# Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

> **NCT02567409** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 87 (actual)

## Conditions studied

- Metastatic Bladder Urothelial Carcinoma
- Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
- Metastatic Ureter Urothelial Carcinoma
- Stage IV Bladder Urothelial Carcinoma AJCC v7

## Interventions

- **DRUG:** Berzosertib
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine Hydrochloride

## Key facts

- **NCT ID:** NCT02567409
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-31
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-04-25
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567409, "Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02567409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*